News >

High Response Rate in Histiocytic Disease With MEK Inhibition

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 03, 2018

Eli Diamond, MD
Eli Diamond, MD
The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders, according to results of a phase II trial presented at the 2017 ASH Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x